Advertisement

The relaxation responses to corticotropin-releasing factor in rat aorta are endothelium dependent and gestationally regulated

      Abstract

      OBJECTIVE: Our purpose was to examine the hypothesis that the relaxant response to corticotropin-releasing factor is endothelium dependent and changes during pregnancy. STUDY DESIGN: Relaxant responses to cumulative concentrations of corticotropin-releasing hormone were measured in rings of thoracic aorta, precontracted with phenylephrine, from pregnant and nonpregnant female rats. Each group consisted of 5 to 10 rats. RESULTS: The relaxation induced by corticotropin-releasing factor in aortic rings from nonpregnant rats decreased after deendothelization and treatment with Nω-nitro-l-arginine methyl ester (a nitric oxide synthase inhibitor), LY-83,583 (a guanylate cyclase inhibitor), or α-helical corticotropin-releasing factor 9-41 (a corticotropin-releasing factor antagonist). The percent decrease in relaxation at 1 nmol/L of corticotropin-releasing factor was about 88% with deendothelization, 100% with Nω-nitro-l-arginine methyl ester, 76% with LY-83,583, and 100% with α-helical corticotropin-releasing factor 9-41. The responses to corticotropin-releasing factor in intact rings from rats in early pregnancy were not significantly different from those in the nonpregnant female rats, but the responses were decreased during the later stages of gestation (percent decrease in relaxation at 1 nmol/L of corticotropin-releasing factor about 71% at day 20 and 98% at term). The relaxation induced by corticotropin-releasing factor during pregnancy was also inhibited by deendothelization, Nω-nitro-l-arginine methyl ester, or LY-83,583. CONCLUSIONS: The relaxant response to corticotropin-releasing factor in the rat aorta is endothelium dependent and is mediated by the nitric oxide–cyclic guanosine monophosphate pathway. The receptor involved in this effect is α-helical corticotropin-releasing factor 9-41 sensitive. This inhibitory response is unchanged during early pregnancy but reduced toward the end of gestation. (Am J Obstet Gynecol 1997;176:234-40.)

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Jones MT
        • Gillham B
        • Hillhouse EW
        The nature of corticotropin releasing factor from rat hypothalamus in vitro.
        Fed Proc. 1977; 36: 2104-2109
        • Rivier C
        • Brownstein M
        • Spiess J
        • Rivier J
        • Vale W
        In vivo corticotropin-releasing factor–induced secretion of adrenocorticotropin, beta-endorphin and corticosterone.
        Endocrinology. 1982; 110: 272-278
        • Brown MR
        • Fisher LA
        • Spiess J
        • Rivier J
        • Rivier C
        • Vale W
        Comparison of biologic actions of corticotropin-releasing factor and sauvagine.
        Regul Pept. 1982; 4: 107-114
        • Fisher LA
        • Jessen G
        • Brown MR
        Corticotropin-releasing factor (CRF): mechanisms to elevate arterial pressure and heart rate.
        Regul Pept. 1983; 5: 153-161
        • Gardiner SM
        • Compton AM
        • Bennet T
        Regional haemodynamic effects of depressor neuropeptides in conscious, unrestrained, Long Evans and Brattleboro rats.
        Br J Pharmacol. 1988; 95: 197-208
        • Pralong FP
        • Corder R
        • Gaillard RC
        Responses of the pituitary-adrenal axis to infusions of corticotropin-releasing factor, vasoactive intestinal peptide and other depressor agents.
        Regul Pept. 1991; 32: 217-226
        • Corder R
        • Turnill D
        • Ling N
        • Gaillard RC
        Attenuation of corticotropin-releasing factor–induced hypotension in anesthetized rats with the CRF antagonist, α-helical CRF 9-41; comparison with effect on ACTH release.
        Peptides. 1992; 13: 1-6
        • Lei S
        • Richter R
        • Bienert M
        • Mulvany MJ
        Relaxing actions of corticotropin-releasing factor on rat resistance arteries.
        Br J Pharmacol. 1993; 108: 941-947
        • Dashwood MR
        • Andrews HE
        • Wei ET
        Binding of [125I] Tyr-corticotropin-releasing factor to rabbit aorta is reduced by removal of the endothelium.
        Eur J Pharmacol. 1987; 135: 111-112
        • Campbell EA
        • Linton EA
        • Wolfe CD
        • Scraggs PR
        • Jones MT
        • Lowry PJ
        Plasma corticotropin-releasing hormone concentrations during pregnancy and parturition.
        J Clin Endocrinol Metab. 1987; 64: 1054-1059
        • Sasaki A
        • Shinkawa O
        • Margioris AN
        • Liotta AS
        • Sato S
        • Murakami O
        • et al.
        Immunoreactive corticotropin-releasing hormone in human plasma during pregnancy, labor and delivery.
        J Clin Endocrinol Metab. 1987; 64: 224-229
        • Frim DM
        • Emanuel RL
        • Robinson BG
        • Smas CM
        • Asler GK
        • Majzoub JA
        Characterization and gestational regulation of corticotropin-releasing hormone messenger RNA in human placenta.
        J Clin Invest. 1988; 82: 287-292
        • Riley SC
        • Walton JC
        • Herlick JM
        • Challis JR
        The localization and distribution of corticotropin-releasing hormone in the human placenta and fetal membranes throughout gestation.
        J Clin Endocrinol Metab. 1991; 72: 1001-1007
        • Poston L
        • McCarthy AL
        • Ritter JM
        Control of vascular resistance in the maternal and feto-placental arterial beds.
        Pharmacol Ther. 1995; 65: 215-239
        • Inagami T
        • Naruse M
        • Hoover R
        Endothelium as an endocrine organ.
        Annu Rev Physiol. 1995; 57: 171-189
        • Tare M
        • Parkington HC
        • Coleman HA
        • Neild TO
        Hyperpolarization and relaxation of the arterial smooth muscle caused by nitric oxide derived from the endothelium.
        Nature. 1990; 346: 69-71
        • Clifton VL
        • Read MA
        • Leitch IM
        • Giles WB
        • Boura ALA
        • Robinson PJ
        • et al.
        Corticotropin-releasing hormone-induced vasodilatation in the human fetal-placental circulation: involvement of the nitric oxide-cyclic guanosine 3`,5`-monophosphate-mediated pathway.
        J Clin Endocrinol Metab. 1995; 80: 2888-2893
        • Kiang JG
        Corticotropin-releasing factor increases [Ca2+]i via receptor-mediated Ca2+ channels in human epidermoid A-431 cells.
        Eur J Pharmacol. 1994; 267: 135-142
        • Schini-Kerth VB
        • Vanhoutte PM
        Nitric oxide synthases in vascular cells.
        Exp Physiol. 1995; 80: 885-905
        • Lüscher TF
        • Tanner FC
        Endothelial regulation of vascular tone and growth.
        Am J Hypertens. 1993; 6: 283S-293S
        • Tropper PJ
        • Warren WB
        • Jozak SM
        • Conwell IM
        • Stark RI
        • Goland RS
        Corticotropin releasing hormone concentrations in umbilical cord blood of preterm fetuses.
        J Dev Physiol. 1992; 18: 81-85
        • Giles WB
        • McLean M
        • Davies JJ
        • Smith R
        Abnormal umbilical artery Doppler waveforms and cord blood corticotropin-releasing hormone.
        Obstet Gynecol. 1996; 87: 107-111
        • Clifton VL
        • Read MA
        • Leitch IM
        • Boura ALA
        • Robinson PJ
        • Smith R
        Corticotropin-releasing hormone induced vasodilation in the human fetal placental circulation.
        J Clin Endocrinol Metab. 1994; 79: 666-669
        • Friedman SA
        • Lubarsky SL
        • Ahokas RA
        • Nova A
        • Sibai BM
        Preeclampsia and related disorders: clinical aspects and relevance of endothelin and nitric oxide.
        Clin Perinatol. 1995; 22: 343-355
        • Yallampalli C
        • Garfield RE
        Inhibition of nitric oxide synthesis in rats during pregnancy produces signs similar to those of preeclampsia.
        Am J Obstet Gynecol. 1993; 169: 1316-1320